Citations

Clear

137 citation(s) found for "Stroger, John H".

Impact of amyloid cardiomyopathy diagnosis on heart failure readmission and length of stay
Masri, Abdallah Fawaz, Vardar, Ufuk , Jabbar, Umair , Murthi, Mukunthan , Malhotra, Saurabh

Mayo Clinic

Baylor University Medical Center Proceedings | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.1080/08998280.2026.2717973 | PMID 42635388 Get It

Natural history of Impella 5.5 in patients with cardiogenic shock and small left ventricular cavities
Desai, Aarti, Wlodkowski, Peter, Klingbiel, Rebecca, Alak, Çetin , Ruiz, Jose, Shapiro, Anna, Martin, Archer, Nativi, Jose, Goswami, R., Klingbeil, Rebecca , Mautong, Hans , Klingbeil, R. , Ruiz, Jose , Nativí, Jose

Mayo Clinic

Frontiers in Cardiovascular Medicine | August 5, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2026.1893068 | PMID 42630958 Get It

The Impella 5.5 is an axillary mechanical circulatory support device used in patients with cardiogenic shock, but those with small left ventricular (LV) cavities may be at risk for suction events, hemolysis, malpositioning, hypoperfusion, and LV injury. Informally accepted guidelines, extrapolated from durable LVAD studies, suggest a minimum left ventricular internal dimension in diastole (LVIDd) of 58 mm, with some clinical practices using a more stringent ≤52 mm cutoff. We retrospectively analyzed 154 consecutive patients supported with Impella 5.5 between January 2020 and December 2024. Overall, 38 patients had an LVIDd ≤58 mm, and 116 had an LVIDd >58 mm; a key subgroup of 21 patients presented with a very small LVIDd of ≤52 mm]. Baseline demographics, comorbidities, body mass index, and renal function were similar [across groups], although those with larger LVIDd had lower ejection fractions (16% vs. 24%, p = 0.001). Median support duration was 24 days in all groups, and pre- and post-implant hemodynamic and laboratory improvements were comparable. Rates of transplantation (79% vs. 90%, p = 0.088) and LVAD implantation (2% vs. 6%, p = 0.159) did not differ significantly in the ≤58 mm cohort. Notably, within the ≤52 mm subgroup, 90-day survival remained high at 90.5% ( p = 0.336), with significant improvements in right atrial pressure (17 to 10 mmHg, p = 0.041), mean pulmonary artery pressure (36 to 26 mmHg, p = 0.008), and eGFR (45 to 57 mL/min/1.73m 2 , p = 0.003). Remarkably, native cardiac recovery was observed exclusively in the smaller LV cohorts, occurring in 11% of the ≤58 mm group ( p = 0.003 vs. 0%, p = 0.003) and reaching 19% in the ≤52 mm group (vs. 0% in larger cavities, p < 0.001), while durable LVAD escalation was entirely avoided in the ≤52 mm cohort (0% vs. 6%). Ninety-day event-free survival was excellent across all cohorts 92% vs. 96% in the primary analysis, with no major device-related complications, suction events, clinically significant hemolysis, bleeding, stroke, or escalation to Bi-VAD support. These findings strongly support the safety and feasibility of Impella 5.5 in extremely constrained, small LV cavities.
Comparative evaluation of left atrial appendage occlusion and oral anticoagulation: a Bayesian meta-analysis of randomized controlled trials
Athmakuri, Krishna , Nandyal, Shreyas , Pamreddy, Hrushikesh Reddy , Vinjamuri, S. , Lingamsetty, Shanmukh Sai Pavan , Mahajan, Anushka Vishwas , Hussain, Muqaddas , Chaliki, Hari P. , Srivathsan, Komandoor , Athmakuri, Krishna Saketh , Nandyal, Shreyas Raghavan , Vinjamuri, Saketh , Lingamsetty, Shanmukh S P , Srivathsan, Komandoor , Mahajan, Anushka

Mayo Clinic

Europace | July 23, 2026 | Volume: 28 | Issue: 7 | Pages: No page available

10.1093/europace/euag163 | PMID 42486485 Get It

Abstract Aims Randomized trials comparing percutaneous left atrial appendage occlusion (LAAO) with oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation have yielded conflicting results across device generations and anticoagulant eras. This Bayesian meta-analysis of randomized trials aimed to compare LAAO vs. OAC for stroke or systemic embolism (SSE) and non-procedural clinically relevant bleeding (CRB). Methods and results We conducted a systematic search across five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane CENTRAL) to identify randomized trials of LAAO vs. OAC. Primary outcomes of stroke or systemic embolism, non-procedural CRB and clinical benefit composite were estimated using a Bayesian hierarchical random effects model and findings confirmed across robust sensitivity and subgroup analyses. Posterior probabilities for superiority, non-inferiority and equivalence were estimated using clinically meaningful margins. Six randomized trials including 7004 participants in the intention-to-treat groups, were analysed. LAAO was not associated with lower SSE vs. OAC (pooled RR, 1.11; 95% CrI, 0.80–1.49), with a 74.6% posterior probability of favouring OAC. The posterior probability of crossing non-inferiority was P(HR < 1.4) of 89%. In contrast, LAAO reduced non-procedural CRB (pooled RR, 0.59; 95% CrI, 0.45–0.78). The net clinical benefit composite, pooling contemporary trials, demonstrated a pooled RR of 0.90 (95% CrI 0.51–1.50), with P(RR < 1) of 76%, with substantial heterogeneity for this outcome. Conclusion This Bayesian meta-analysis found no clear evidence supporting clinically meaningful non-inferiority of LAAO over OAC for stroke prevention. Despite reduced non-procedural bleeding, LAAO did not demonstrate a similar reduction in major bleeding.
Real-world use of fruquintinib in refractory metastatic colorectal cancer in the United States.
Bansal, Vasu , Adhikari, Aakriti , Saha, Souvik , Srinivasan, Varshini , Maurya, Priyanshi, Goyal, Mayank, Al-sadi, Anas, Harris, Audrey, McConville, Haley, Mahadevia, Himil, Singh, Anmol , Al-sadi, Anas , Mahadevia, Himil , Mosalem, Osama

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e15713 Get It

e15713 Background: Fruquintinib demonstrated overall survival benefit in heavily pretreated metastatic colorectal cancer (mCRC) in FRESCO and FRESCO-2. The FDA approved fruquintinib on Nov 8, 2023 for adult patients with mCRC after standard chemotherapy plus anti-VEGF therapy, with anti-EGFR therapy when appropriate (e.g., RAS wild-type). Observed geographic variation in post-approval uptake suggests potential disparities in the delivery of evidence-based medicine across U.S. regions. Methods: We conducted a retrospective cohort study using Epic Cosmos, a database of over 300 million patient records from over 1,500 hospitals nationwide. We identified adults with metastatic colorectal cancer (mCRC) with prior standard systemic therapy exposure and recorded fruquintinib exposure following FDA approval beginning Nov 8, 2023. Fruquintinib uptake was analyzed by U.S. Census region and state, expressed as the proportion of eligible mCRC patients receiving fruquintinib within each geography. Results: Among 116,116 pre-treated mCRC patients, 6,722 (5.79%) had recorded fruquintinib exposure during the post-approval period. Uptake varied nearly five-fold across states (2.27%–11.33%) (Table). High-uptake states were disproportionately concentrated in the central U.S./Midwest, whereas multiple low-uptake states were observed in the West and Northeast, suggesting broader regional variation beyond state-to-state differences. Conclusions: In a large national EHR-derived cohort of pre-treated mCRC patients after U.S. approval, fruquintinib uptake demonstrated substantial geographic variation. These findings raise concern for inequities in delivery of evidence-based later-line therapy and highlight the need to identify modifiable system- and site-level drivers (e.g., access, referral patterns, treatment infrastructure) to promote equitable adoption. Fruquintinib uptake among eligible metastatic colorectal cancer patients by U.S. state. Rank Geography Eligible mCRC (N) Fruquintinib uptake (%) Overall Overall 116,116 5.79 Top 1 Oklahoma 1,236 11.33 2 Kansas 1,312 10.75 3 Indiana 2,448 10.70 4 Missouri 1,521 9.47 5 Connecticut 2,208 9.24 Bottom 1 Washington 1,232 2.27 2 Nevada 441 2.72 3 Rhode Island 476 2.73 4 Tennessee 1490 2.82 5 Maine 614 2.93 Fruquintinib uptake is reported as the proportion of eligible pre-treated metastatic colorectal cancer (mCRC) patients with recorded fruquintinib exposure following U.S. FDA approval. States are ranked by uptake percentage.
The Prevalence of Fibromyalgia in the General Population and At-Risk Subpopulations: A Systematic Review and Meta-Analysis
D'Souza, R. S., Klasova, Johana, Morsi, Mahmoud, Vincent, Ann, Mohabbat, Arya B. , Whitfield, Savannah, Radlicz, Christopher, Zhitnitsky, Michael, Saini, Camille , Al-Hindawi, Ahmed, Lopez, Kalei, To, Jimmy, Graca, Mateusz, Gill, Benjamin, Her, Yeng F , Hussain, Nasir, D’Souza, Ryan S. , D'Souza, Ryan S , Klasová, Johana , Morsi, Mahmoud , Vincent, Ann , Radlicz, Christopher M. , Sheen, Soun , Wang, Daniel , Zhitnitsky, Michael D., Saini, Chandan, Al‐Hindawi, Ahmed , To, Jimmy, Chitneni, Ahish , Graca, Mateusz, Prokop, Larry J. , Hussain, Nasir

Mayo Clinic

Anesthesia & Analgesia | May 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1213/ane.0000000000008098 | PMID 42201834 Get It

Estimates of fibromyalgia prevalence vary widely worldwide due to differences in diagnostic criteria, study methodology, and population characteristics. Accurate estimates are essential to inform population-level surveillance, guide resource allocation, and highlight disparities in disease recognition and access to care. The objective of this systematic review and meta-analysis was to determine the global prevalence of fibromyalgia in the general population, and secondarily to identify factors moderating prevalence variation and to assess prevalence in defined at-risk subpopulations. Pooled prevalence estimates with 95% confidence intervals (CIs) were calculated using the inverse variance heterogeneity model with Freeman–Tukey transformation. Subgroup analyses were performed by sex, diagnostic criteria, country, and other study characteristics, and meta-regression assessed moderators including publication year and Human Development Index (HDI). Of 21,645 records identified, 1,728 underwent full-text review and 882 studies were included in the final analysis. Across 38 countries and 30,070,032 individuals (188 studies), the pooled fibromyalgia prevalence in the general population was 1.40% (95% CI, 0.49–2.47), with substantial heterogeneity (I 2 = 100%) and very low certainty of evidence. Among at-risk subpopulations (9,771,123 participants; 768 studies), prevalence was markedly higher in autoimmune and inflammatory conditions, such as chronic urticaria (37.1%), interstitial cystitis (30.8%), systemic sclerosis (20.6%), celiac disease (20.5%), and inflammatory bowel disease (19.9%), and elevated in chronic pain, rheumatologic, and post-infection cohorts. Meta-regression identified publication year (β = 0.008, P < .001) and HDI (β = 0.725, P = .002) as significant moderators of prevalence. In conclusion, fibromyalgia affects 1% to 2% of the global population, with substantially higher rates in at-risk subpopulations. Temporal and socioeconomic trends emphasize diagnostic inconsistency and global disparities in care.
Change in opioid use following spinal cord stimulation: a systematic review and meta-analysis
Soleymani, Hunter , Morsi, Mahmoud , Kopacz, Kira, Karri, Jay , Goudman, Lisa , Hussain, Nasir , Javed, Saba , D’Souza, Ryan S. , D'Souza, Ryan S , Karri, Jay , Javed, Saba

Mayo Clinic

Regional Anesthesia & Pain Medicine | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: rapm-2026-107603

10.1136/rapm-2026-107603 | PMID 42120103 Get It

Importance Chronic pain is a leading cause of disability, and many affected patients rely on long-term opioid therapy despite its unfavorable adverse effect profile. Spinal cord stimulation is an established therapy for chronic pain that may secondarily reduce opioid consumption by providing sustained analgesia. Objective To quantify changes in opioid use following spinal cord stimulation implantation for the treatment of chronic pain through a systematic review and meta-analysis. Data sources We conducted a comprehensive search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus from each database’s inception to July 1, 2024. Study selection We included studies describing patients who underwent spinal cord stimulator implantation for the treatment of chronic pain. A total of 2,784 potential studies were identified and screened by multiple independent reviewers, yielding a final total of 43 studies included in the systematic review. Data extraction and synthesis Data extraction was completed by multiple independent reviewers following Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Meta-analysis Of Observational Studies in Epidemiology guidelines. A random effects model with Hartung-Knapp-Sidik-Jonkman adjustment was used to estimate pooled estimates. Certainty assessment was performed following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Main outcome(s) and measure(s) The primary outcomes were change in continuous opioid use (ie, morphine milligram equivalent (MME)) and categorical opioid use (yes/no) from preimplantation to 12 months following spinal cord stimulator implantation. Results Meta-analysis of 12 month continuous MME use comprising 22 study comparisons (1,666 individuals) revealed a weighted mean difference of −18.06 MME (95% CI −24.41 to −11.70; 95% prediction interval −38.29 to 2.17; p<0.001). Meta-analysis of categorical opioid use at 12 months comprising 24 study comparisons (1,527 individuals) revealed an OR of 0.47 (95% CI 0.30 to 0.75; 95% prediction interval 0.10 to 2.11; p=0.003), signifying lower odds of opioid continuation. Conclusions and relevance Spinal cord stimulation is associated with reduced opioid dose consumption and increased odds of opioid cessation at 12 months postimplantation compared with baseline in patients with chronic pain; however, both of these conclusions are supported by evidence of very low GRADE certainty. PROSPERO registration number CRD42024574921.
Impact of a web‐based breast cancer surgery decision aid on knowledge and perceptions of feeling informed in clinics that care for socioeconomically disadvantaged patients: An Alliance Clinical Trial (A231701CD)
Schumacher, Jessica R. , Hanlon, Bret M., Zahrieh, David , Tucholka, Jennifer L. , McKinney, Grace, Tan, Angelina D., Breuer, Catherine R. , Bailey, Lisa, Higham, Anna M. , Wecsler, Julie S. , Arnold, Alicia H, Froix, Anthony J. , Dull, Scott, Abbott, Andrea M., Fine, Stephanie , McGuire, Kandace P. , Seydel, Anna S. , McNamara, Patricia, Chow, Selina , Neuman, Heather B. , Hanlon, Bret M. , Hanlon, Bret M , Arnold, Alicia , Abbott, Andrea M , Neuman, Heather B , Rathouz, Paul J. , McKinney, Grace, Bailey, Lisa, Abbott, Andrea M.

Mayo Clinic

Cancer | February 11, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70314 | PMID 41669989 Get It

Abstract Objective To test the effectiveness of a surgical web‐based decision aid (DA) in improving knowledge. Summary of Background Data DAs support decision making by providing information about the options. Methods A stepped wedge trial was conducted in 10 National Cancer Institute Community Oncology Research Program clinics (Alliance for Clinical Trials in Oncology). Clinics were randomized to time of transition from usual care (UC) to delivery of a web‐based DA. Patients with stage 0 through 3 breast cancer being considered for surgery were enrolled. Knowledge (primary outcome) was measured using the Breast Cancer Surgery Decision Quality Instrument and patients were asked, “How informed do you feel?” Intervention effects were tested with linear mixed‐effects models, accounting for surgeon and clinic‐level clustering, time, and enrollment after COVID. Additional models controlled for demographics. Results A total of 44% of DA arm patients reviewed the DA and 58% in UC arm reported reviewing “any information.” Being in the DA arm versus UC was not associated with knowledge. However, “review of information” was associated with higher knowledge. In addition, non‐White race and lower education were associated with lower knowledge. The DA arm was associated with higher perceptions of feeling informed (parameter estimate 1.36; 95% CI, 0.18–2.55; p = .02); this persisted even when controlling for review of information or demographics. Conclusion Improved knowledge was not demonstrate with a web‐based DA versus UC. Interestingly, the DA was associated with a higher likelihood of feeling informed. Future research will explore the discrepancy between patients feeling informed but having low knowledge, especially for disadvantaged patients. Trial Registration ClinicalTrials.gov Identifier: NCT0376600
Determination of Adult Critical Care Physician Core Knowledge and Skills: Results of a Multidisciplinary, Modified Delphi Process
Tisherman, Samuel A. , Spevetz, Antoinette, Farmer, Joseph C. , Michener, Ed, Sreedharan, Roshni , Strickler, Samantha , Cuschieri, Joseph , Ellender, Timothy J., Kaups, Krista L. , Keegan, Mark T. , Lee, May M. , Malaiyandi, Deepa , Michetti, Christopher P. , Mohr, Nicholas M. , Moitra, Vivek K. , O’Neil, Kevin , Palmieri, Tina L. , Park, Pauline K., Raksin, P B , Shapshak, Angela Hays , Siddiqui, Shahla , Stein, Deborah M. , Timmons, Shelly D. , Vespa, Paul , Wessman, Brian T. , Wittwer, Erica D. , Medicine, on behalf of the Adult Critical Care Physician Core Knowledge and Skills Task Force of the Society of Critical Care, Farmer, J Christopher, Mohr, Nicholas M , Kashyap, Rahul , Leichtle, Stefan W. , Chang, Cherylee W. J. , Yataco, Angel Coz , Dudzinski, David M. , Emlet, Lillian L. , Fahy, Brenda G. , Geller, Bram J. , Hennessey, Erin , Park, Pauline K. , Pathak, Abhijit S. , Medicine, on behalf of the Adult Critical Care Physician Core Knowledge and Skills Task Force of the Society of Critical Care, Siddiqui, Shahla

Mayo Clinic

Critical Care Medicine | December 9, 2025 | Volume: 54 | Issue: 2 | Pages: 224-233

10.1097/ccm.0000000000006978 | PMID 41363909 Get It

Objectives: In the United States, training for physicians who manage critically ill adult patients (intensivists) evolved through parallel subspecialty critical care medicine (CCM) pathways with significant commonality. The Society of Critical Care Medicine Adult Critical Care Physician Core Knowledge and Skills Task Force aimed to delineate the common core knowledge and skills required of all intensivists. Design: A master list of content areas and procedural skills was compiled from all CCM subspecialty program requirements and blueprints of the certification examinations. Using a modified Delphi approach, participants were asked to categorize the knowledge items as “advanced knowledge is essential,” “general, but not advanced, knowledge is essential,” or “knowledge is not essential.” Procedures were categorized as “intensivist performs routinely,” “intensivist only performs in an emergency,” or “intensivist knows” about the procedure. Setting: Representatives from CCM stakeholder organizations, including accreditation and certification organizations, critical care societies, and program directors’ societies, were invited to participate. SUBJECTS: Members of the Adult Critical Care Physician Core Knowledge and Skills Task Force of the Society of Critical Care Medicine. Interventions: For the first two rounds of the modified Delphi process, Research Electronic Data Capture was used. For the third and fourth rounds, the process was completed through online meetings with Zoom (Zoom Video Corporations, San Jose, CA) utilizing Zoom’s polling feature. Measurements and Main Results: A total of 541 items were determined to be essential, with 145 requiring advanced knowledge and 323 requiring general knowledge. For 73 items, consensus regarding advanced vs. general could not be achieved, but they remained essential. Only eight items were felt to be nonessential. Of the 16 procedures, most were categorized as “intensivist performs.” Conclusions: The large number of items included in the list of essential knowledge and skills demonstrates the complexity of modern CCM. Utilization of a common framework across the subspecialties of CCM could lead to greater harmonization among the fellowship program requirements and certification examinations.
Simultaneous Heart-Kidney vs. Isolated Heart Transplantation in Advanced Heart Failure with CKD: Insights from a National Inpatient Sample Study
Ghimire, Manoj, Poudel, Sajana , Ghimire, Kalpana , Shrestha, Karun , Subedi, Prakriti , Sangam, Sangam , Bhatta, Gaurab, Mundhra, Gunjan, Madera, Irvianny, Chaudhary, Sanjay, Chang, Bessy Suyin Flores, Ghimire, Manoj, Dandamudi, Mrunalini

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025pr63sjrb Get It

Implantable peripheral nerve stimulation for chronic pain: a systematic review and meta-analysis of analgesic outcomes up to 24 months
D’Souza, Ryan S. , Her, Yeng F , Morsi, Mahmoud , Soleymani, Hunter , Banks, Dylan , Miclau, Theodore , Ekhtiari, Eleena, Cho, David , Hussain, Nasir , Miclau, Theodore A, Hussain, Nasir , D'Souza, Ryan S , Cho, David J , Prokop, Larry J.

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107160

10.1136/rapm-2025-107160 | PMID 41193385 Get It

Background Peripheral nerve stimulation (PNS) has emerged as a promising neurostimulation modality, yet its effectiveness and durability for chronic pain remain uncertain. We conducted a systematic review and meta-analysis to evaluate changes in pain intensity following implantable PNS therapy. Methods Eligible studies included adults (≥18 years) with chronic pain treated with an implantable PNS system, and pain intensity was assessed at baseline and follow-up time points. The primary outcome was change in pain intensity from baseline to 6 months after PNS implantation. Secondary outcomes included changes in pain intensity at 3, 12 and 24 months after PNS implantation. Standardized mean differences (Hedges’ g ) were pooled using a random-effects model. Results A total of 106 studies comprising 9272 patients were included. PNS was associated with large, statistically significant reductions in pain intensity from baseline to all time points: 3 months (Hedges’ g 2.92; 95% CI 2.62 to 3.21), 6 months (Hedges’ g 3.08; 95% CI 2.68 to 3.48), 12 months (Hedges’ g 2.68; 95% CI 2.30 to 3.05) and 24 months (Hedges’ g 2.08; 95% CI 1.68 to 2.48) (all p<0.001). However, the certainty of evidence as assessed by the Grading of Recommendations Assessment, Development and Evaluation criteria was rated as low for the primary outcome, due to pooling from observational studies, risk of bias, and heterogeneity (statistical, clinical and methodological). Subgroup analyses revealed no differences by study design or device type, while smaller effect sizes were reported in industry-funded studies and those with declared conflicts of interest. The largest effect sizes were observed in pelvic and upper extremity pain, whereas the smallest in truncal pain. Conclusion Implantable PNS provides persistent and clinically meaningful analgesia for chronic pain, with benefits sustained up to 24 months. These findings support broader clinical adoption and provide evidence to inform pay0r coverage and policy decisions.